Company Overview
Company Type: Private Company
Website: my01.io
Number of Employees: -
Year Founded: 2015
Total Amount Raised (CAD mm)†: 16.84
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
MY01 Inc. designs and develops a digital microsensing technology solution for acute compartment syndrome. Its device is used to monitor continuous pressure in muscle compartments. The company’s solution also includes a wireless and app-based system that enables ongoing care team collaboration. MY01 Inc. was founded in 2015 and is based in Montreal, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Harvey, Ed 
Chairman of the Board & Chief Medical Officer
Allan, Charles 
CEO & Director
Bataille, Olivier 
Chief Operations Officer
Xereas, George 
Chief Technology Officer
Lambo, Gino 
Director of Sales
Sanscartier, Simon 
Vice President of Europe & Emerging Markets
Merkel, Jay 
Chief Commercial Officer

Key Board Members
Name
Title
Harvey, Ed 
Chairman of the Board & Chief Medical Officer
Allan, Charles 
CEO & Director
Henderson, Glenn 
Director
McLeod, Andrew 
Director
Mikola, Mike 
Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
400 Boul de Maisonneuve Ouest Suite 700 | Montreal, QC | H3A 1L4 | Canada
Phone: 855-799-6901   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Desjardins Capital
Apr-11-2023
Unknown
-
Series A
Fondaction
Apr-11-2023
Minority
-
Series A
Investissement Québec
Apr-11-2023
Minority
-
Series A
Anges Québec
Jun-12-2019
Minority
-
Venture
Invest Nova Scotia
Jun-12-2019
Minority
-
Venture


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-11-2023
Apr-11-2023
Private Placement
Target
MY01 Inc.
Investissement Québec,Fondaction,Desjardins Capital

12.50
Jun-12-2019
Jun-12-2019
Private Placement
Target
MY01 Inc.
MEDTEQ, Le consortium de recherche et d'innovation en technologies médicales du Québec,Anges Québec,Invest Nova Scotia,Real Investment Management Inc. Buyer Funds:Anges Québec Capital Fund

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-20-2023
Company Conference Presentations
MY01 Inc. Presents at LSI Europe '23 Emerging MedTech Summit, Sep-20-2023 11:55 AM
Apr-11-2023
Private Placements
MY01 Inc. announced that it has received $12.5 million in funding from Investissement Québec, Fondaction, Desjardins Capital
Mar-21-2023
Company Conference Presentations
MY01 Inc. Presents at LSI USA ’23 Emerging Medtech Summit, Mar-21-2023 11:25 AM
Nov-22-2022
Executive/Board Changes - Other
MY01 Inc. Appoints Jay Merkel as Chief Commercial Officer
Oct-12-2022
Company Conference Presentations
MY01 Inc. Presents at 38th Annual Meeting 2022, Oct-12-2022


Advisors
Private Placement Advisors
Fasken Martineau DuMoulin LLP


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Harvey, Ed 
Chairman of the Board & Chief Medical Officer
855-799-6901
-
ed.harvey@my01.io
Allan, Charles 
CEO & Director
855-799-6901
-
charles.allan@my01.io
Henderson, Glenn 
Director
855-799-6901
-

McLeod, Andrew 
Director
855-799-6901
-

Mikola, Mike 
Director
855-799-6901
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Harvey, Ed 
Chairman of the Board & Chief Medical Officer
855-799-6901
-
ed.harvey@my01.io
Allan, Charles 
CEO & Director
855-799-6901
-
charles.allan@my01.io
Bataille, Olivier 
Chief Operations Officer
855-799-6901
-

Xereas, George 
Chief Technology Officer
855-799-6901
-
george.xereas@my01.io
Lambo, Gino 
Director of Sales
855-799-6901
-
gino.lambo@my01.io
Sanscartier, Simon 
Vice President of Europe & Emerging Markets
855-799-6901
-
simon.sanscartier@my01.io
Merkel, Jay 
Chief Commercial Officer
855-799-6901
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
